<DOC>
	<DOCNO>NCT00165464</DOCNO>
	<brief_summary>This phase II study taxotere , cisplatin irinotecan ( CPT-11 ) use combination treat metastatic esophageal gastric cancer effort see effect ( good bad ) combination may patient cancer .</brief_summary>
	<brief_title>Taxotere , Cisplatin Irinotecan ( CPT-11 ) Esophagogastric Cancer</brief_title>
	<detailed_description>- Taxotere , cisplatin irinotecan administer patient weekly 2 week follow one week rest period ( 1 cycle 3 week ) . - Patients also receive corticosteroid , intravenous hydration anti-emetic therapy prior treatment . - A physical exam bloodwork do week treatment every 2 cycle , reassessment tumor image method determine baseline size conduct . - Patients remain study unless disease progression intolerable toxicity occur .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically confirm , incurable esophageal gastric carcinoma ( carcinoma = adenocarcinoma squamous cell carcinoma ) Measurable disease &gt; 1cm ( long diameter ) spiral CT scan &gt; 2cm radiographic technique . Lesions must measurable least one dimension . Bone lesion , ascites effusion measurable . Irradiated lesion measurable yet lesion arise previously irradiate field measurable . Age 18+ year . ECOG performance status 0 1 . Life expectancy great 12 week . Adequate bone marrow function . Adequate renal function : creatinine equal less 1.5 mg/dl . SGOT le 2.5 x institutional upper limit normal alkaline phosphatase within institutional upper limit normal . Alkaline phosphatase le 4.0 x upper limit normal SGOT within institutional upper limit normal . For patient SGOT alkaline phosphatase elevation , SGOT must less 1.5 x institutional upper limit normal alkaline phosphatase must less 2.5 x institutional upper limit normal . For patient liver metastasis , however , SGOT may &lt; 3.0 x institutional upper limit normal alkaline phosphatase may &lt; 5.0 x institutional upper limit normal long total bilirubin within institutional upper limit normal . No prior chemotherapy ( except part pre postoperative therapy , complete &gt; 1 year prior start date protocol ) . Patients receive prior pelvic radiation therapy ineligible . Other prior radiation therapy , however , permit , provide least 4 week elapse since completion therapy initiation protocol . No myocardial infarction past six month . No major surgery past three week . No uncontrolled serious medical psychiatric illness . No uncontrolled diarrhea . Patients peripheral neuropathy &gt; grade 1 exclude . Women childbearing potential must negative pregnancy test . Men woman childbearing potential must use adequate contraception . No clinically apparent central nervous system metastases carcinomatous meningitis . No active malignancy nonmelanoma skin cancer insitu cervical carcinoma . A resected cancer ( insitu carcinoma ) must demonstrate evidence recurrence least 3 year . Patients history severe hypersensitivity irinotecan , cisplatin , taxotere drug formulate polysorbate 80 must exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Esophageal Cancer</keyword>
	<keyword>Gastric Cancer</keyword>
	<keyword>GE Junction</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Taxotere</keyword>
	<keyword>CPT-11</keyword>
	<keyword>Irinotecan</keyword>
</DOC>